NCT05443737 Evaluation of a Telehealth Oncofertility Care Intervention in Adolescent and Young Adult Cancer Patients
| NCT ID | NCT05443737 |
| Status | Recruiting |
| Phase | Phase 3 |
| Sponsor | University of California, San Diego |
| Condition | Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 2,800 participants |
| Start Date | 2022-01-01 |
| Primary Completion | 2027-08-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 3 trials are large pivotal studies comparing the treatment to current standard of care or placebo. Your participation directly contributes to the evidence needed for regulatory approval.
This trial targets 2,800 participants in total. It began in 2022-01-01 with a primary completion date of 2027-08-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this study is to evaluate the effectiveness of a multi-component intervention to improve young cancer survivors' engagement in goal-concordant oncofertility care, concurrently with observing and gathering information on how the intervention is implemented. The investigators hypothesize that implementation of the intervention will result in increased young cancer survivors' engagement in goal-concordant oncofertility care.
Eligibility Criteria
Inclusion Criteria: * Newly diagnosed cancer or cancer relapse * Primary language English or Spanish * Receiving oncology care at participating clinical sites * Ages 0 to 42 years if female * Ages 0 to 50 years if male Exclusion Criteria: * Non-melanoma skin cancer, because primary treatment is excision with no infertility risk * Metastatic/Stage IV non-thyroid solid tumors, because of poor prognosis
Contact & Investigator
H. Irene Su, MD, MSCE
PRINCIPAL INVESTIGATOR
University of California, San Diego
Frequently Asked Questions
Who can join the NCT05443737 clinical trial?
This trial is open to participants of all sexes, aged 0 Years or older, up to 50 Years, studying Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT05443737 trial and what does that mean for participants?
Phase 3 trials are large-scale studies comparing the new treatment to existing standards of care or a placebo. They provide the evidence needed for regulatory approval. This trial targets 2,800 participants.
Is NCT05443737 currently recruiting?
Yes, NCT05443737 is actively recruiting participants. Contact the research team at hisu@health.ucsd.edu for enrollment information.
Where is the NCT05443737 trial being conducted?
This trial is being conducted at Duarte, United States, El Centro, United States, La Jolla, United States, San Diego, United States.
Who is sponsoring the NCT05443737 clinical trial?
NCT05443737 is sponsored by University of California, San Diego. The principal investigator is H. Irene Su, MD, MSCE at University of California, San Diego. The trial plans to enroll 2,800 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.